ARCHIVES

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

This article is from The Cancer Letter archive.

Vol. 31 No. 19 | May 13, 2005

Download PDF Visit The Full Archive

Related Articles

NSABP Accrual Slow, But Auditing Called “Impressive”

January 20, 1995

“Clinical research of all kinds in the IRP lacks a rigorous, centralized process for peer review.”

July 21, 1995

Tissue of Origin Test Consistent With Diagnosis In Blinded Validation Study

January 28, 2011

In Brief: McIntyre To Replace Frei As Group Chairman Abeloff, Murphy Nominated For ASCO Presidency

January 26, 1990

Cancer Centers Win Majority Of Grants In Recent NCI RFAs, Klausner Tells AACI.

October 6, 2000

Three Institutes To Test BioMicro’s Microarray Product. GlycoDesign Allowed Patent For Cancer Drug GD0039.

March 1, 2002